Cyrus Biotechnology announces potent in vivo redosability of an engineered IdeS protease for IgG-driven autoimmune disease.

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" ...

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 ...

PGIM Jennison Health Sciences Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its Q3 2024 investor letter: ...

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, ...

This article explores the latest techniques and workflows for purification across biopharmaceuticals including vaccines, ...

If you're interested in trying spirulina, you should know the pros, cons and dosage information before consuming the algae.

Explore how prenatal smoking exposure and genetic predispositions influence Multiple Sclerosis risk, focusing on childhood ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

The Vericheck ddPCR Empty-Full Capsid Kits comprise a capsid detection assay in FAM and an ITR-2 assay in HEX. The ITR-2 ...

Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 62,100 shares, a decline of ...

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...